Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2020 Feb 29

PMID 32110062

Citations 3

Authors

Elaheh Kordzadeh-Kermani

Hossein Khalili

Iman Karimzadeh

Mohammadreza Salehi

Affiliations

Soon will be listed here.

Abstract

The introduction of biologic and targeted immunomodulators is a significant breakthrough in the therapeutic area of various fields of medicine. The occurrence of serious infections, a complication of secondary immunosuppression associated with these agents, leads to increased morbidity and mortality. Implementing preventive strategies could minimize infection-related complications and improve therapeutic outcomes. The purpose of this review is to focus on current evident approaches regarding screening, monitoring, preventing (immunization and chemoprophylaxis), and management of infections in patients who are candidates for about 70 biologic and targeted immunomodulators. Recommendations are based on relevant guidelines, especially the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document series published in 2018.

Citing Articles

Combination of Anti-CD40 and Anti-CD40L Antibodies as Co-Stimulation Blockade in Preclinical Cardiac Xenotransplantation.

Bender M, Abicht J, Reichart B, Neumann E, Radan J, Mokelke M Biomedicines. 2024; 12(8.

PMID: 39200391 PMC: 11351779. DOI: 10.3390/biomedicines12081927.

Advising the immunocompromised traveller: a review of immunocompromise at The London Hospital for Tropical Diseases Travel Clinic between 1st April 2019 and 30th April 2020.

Beer E, Chowdhury H, Carroll B, Luintel A, van Tulleken C, Longley N Trop Dis Travel Med Vaccines. 2024; 10(1):8.

PMID: 38616263 PMC: 11017494. DOI: 10.1186/s40794-024-00217-0.

The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review.

Yarahmadi P, Alirezaei M, Forouzannia S, Naser Moghadasi A Iran J Med Sci. 2021; 46(6):411-419.

PMID: 34840381 PMC: 8611224. DOI: 10.30476/IJMS.2021.88717.1946.

References

Fishman J, Gans H . Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 33(9):e13587. DOI: 10.1111/ctr.13587. View

Souto A, Maneiro J, Salgado E, Carmona L, Gomez-Reino J . Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). 2014; 53(10):1872-85. DOI: 10.1093/rheumatology/keu172. View

Bongartz T, Sutton A, Sweeting M, Buchan I, Matteson E, Montori V . Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295(19):2275-85. DOI: 10.1001/jama.295.19.2275. View

Kaufman M, Pardo G, Rossman H, Sweetser M, Forrestal F, Duda P . Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014; 341(1-2):22-7. DOI: 10.1016/j.jns.2014.03.035. View

Puzanov I, Diab A, Abdallah K, Bingham 3rd C, Brogdon C, Dadu R . Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017; 5(1):95. PMC: 5697162. DOI: 10.1186/s40425-017-0300-z. View

Bresnihan B, Cunnane G . Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am. 2003; 29(1):185-202. DOI: 10.1016/s0889-857x(02)00101-1. View

Bigaut K, De Seze J, Collongues N . Ocrelizumab for the treatment of multiple sclerosis. Expert Rev Neurother. 2018; 19(2):97-108. DOI: 10.1080/14737175.2019.1561284. View

Cohen B . Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis. Neurology. 2019; 92(9):435-436. DOI: 10.1212/WNL.0000000000006924. View

Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr K . Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. CNS Drugs. 2016; 31(1):33-50. PMC: 5225231. DOI: 10.1007/s40263-016-0394-8. View

10.

Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly J, Alanio A . ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016; 71(9):2397-404. DOI: 10.1093/jac/dkw157. View

11.

Ferguson F, Gray N . Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018; 17(5):353-377. DOI: 10.1038/nrd.2018.21. View

12.

Furer V, Rondaan C, Heijstek M, Agmon-Levin N, van Assen S, Bijl M . 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2019; 79(1):39-52. DOI: 10.1136/annrheumdis-2019-215882. View

13.

Barmettler S, Ong M, Farmer J, Choi H, Walter J . Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2019; 1(7):e184169. PMC: 6324375. DOI: 10.1001/jamanetworkopen.2018.4169. View

14.

Wondergem M, Grunberg K, Wittgen B, Sonneveld P, Zweegman S . Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment. Histopathology. 2009; 54(5):631-3. DOI: 10.1111/j.1365-2559.2009.03263.x. View

15.

Harpaz R, Ortega-Sanchez I, Seward J . Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008; 57(RR-5):1-30. View

16.

Williamson E, Berger J . Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies. Neurotherapeutics. 2017; 14(4):961-973. PMC: 5722774. DOI: 10.1007/s13311-017-0570-7. View

17.

Brodmerkel C, Wadman E, Langley R, Papp K, Bourcier M, Poulin Y . Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol. 2013; 12(10):1122-9. View

18.

Issa N, Baden L . Current issues in vaccines for adult patients with hematologic malignancies. J Natl Compr Canc Netw. 2012; 10(11):1447-54. DOI: 10.6004/jnccn.2012.0147. View

19.

Salmon J, Cacoub P, Combe B, Sibilia J, Pallot-Prades B, Fain O . Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. 2015; 1(1):e000034. PMC: 4612695. DOI: 10.1136/rmdopen-2014-000034. View

20.

Mori S, Yoshitama T, Hidaka T, Sakai F, Hasegawa M, Hashiba Y . Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. PLoS One. 2017; 12(6):e0179179. PMC: 5464634. DOI: 10.1371/journal.pone.0179179. View